India, June 17 -- Shares of CERo Therapeutics Holdings, Inc. (CERO) jumped over 70% on Tuesday morning after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia.
CERO is currently trading at $11.90, up $5.03 or 73.27%, on a huge volume of 11.7 million shares, above average volume of 100 thousand, on the Nasdaq. The stock opened its trading at $10.54 after closing Monday at $6.87. The stock has traded between $6.71 and $896.00 in the past 52-week period.
CER-1236 is a therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms al...